I am a firm believer that great sex is one of the most important part of a relationship. When it comes to sexual intimacy, couples need to be more open with their partners about what satisfies them. Given that the two of you share a special bond, there's no reason for you to not be comfortable about discussing what you like - and don't like about sex. After all, an activity that is meant to be enjoyed, should provide fulfillment for both parties.
Premature ejaculation (PE) is when a man ejaculates with little sexual stimulation and before the man wishes.This can lead to a decrease in sexual satisfaction and quality of life for men and their partners. One-in-three men may experience some form of premature ejaculation in their lives, which. negatively impacts their quality of life and sexual satisfaction with their partner.. A survey of more than 12,000 men showed that those with premature ejaculation had experienced less sexual satisfaction. Men with premature ejaculation were also more likely to report having 'little interest in sex' and 'lack of orgasm'. Men with premature ejaculation in this survey also had greater concerns about their overall relationship – sometimes even avoiding relationships altogether.
Many men carry on with their lives hoping that their premature ejaculation will get better with time. The important thing to remember is that premature ejaculation is treatable, and that by speaking to your doctor, you can access a number of effective treatments. One of them is Dapoxetine.
Menarini Philippines continues to promote its Community to Control PE advocacy campaign this 2015 with its Happy Wife, Happy Life event.
Dapoxetine is the first and only drug specifically developed for the treatment of premature ejaculation and is now approved in over 50 countries. Based on robust clinical trials involving over 16,000 men worldwide, dapoxetine is proven to be well-tolerated and to significantly improve all measures of premature ejaculation, including control over ejaculation and sexual satisfaction for the couple. Dapoxetine quickly increases the synaptic levels of serotonin, improving the symptoms of premature ejaculation. Dapoxetine is available by prescription in 30 mg and 60 mg oral tablets and should be taken, on-demand, one to three hours before intercourse with a full glass of water. is indicated for men with premature ejaculation aged between 18 to 64 years, and is clinically proven to work effectively on the first dose. To optimize individual response, dapoxetine should be taken for at least six doses or four weeks. Dapoxetine should not be taken more than what is prescribed, and should not be taken more than once every 24 hours.
Dapoxetine is indicated for men with premature ejaculation aged between 18 to 64 years. Dapoxetine is not recommended for those with significant pathological cardiac conditions, including heart failure, conduction abnormalities (e.g. sick sinus syndrome, heart block or atrioventricular conduction abnormalities), significant ischemic and valvular disease, and history of syncope (fainting).6 Men with current or past mental problems (such as depression, mania, bipolar disorder or schizophrenia), or eye disorders (such as raised intraocular pressure or those at risk of angle closure glaucoma) are advised to seek advice from their physicians before starting treatment with dapoxetine.
Menarini Philippines together with the Philippine Urological Association, boldly launched its Commit to Control PE Advocacy campaign last year to address one of the more pressing issues regarding sexual intimacy - premature ejaculation.
The campaign is meant to make couples more comfortable about discussing their intimacy concerns with each other, without it being a cause of insecurity or dissatisfaction.
Menarini Philippines strongly believes in this advocacy which is often left untreated because it is a topic that is usually considered taboo even in these modern times. The pharmaceutical giant hopes to make a stronger impact among Filipino couples on their campaign this year with more events like this.
Menarini is the world’s largest Italian biopharmaceutical company with a heritage of over 128 years and over 16,000 employees in over 100 countries. Here in Asia-Pacific, Menarini’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region. Menarini Asia-Pacific operates across the entire commercial value chain, from regulatory approval and product launch to lifecycle management with a diverse portfolio of proprietary and partnered brands in key therapeutic fields, including Dermatology, Primary Care, Allergy/Respiratory, Cardiovascular, Select Specialty Care, Men’s Health and Consumer Health.
For further information, please visit: www.menariniapac.com. You can also follow me on Twitter and Instagram: @Dsweetbox.